We are live on ! Find out more
LNAI

Lunai Bioworks

29 hedge funds and large institutions have $6.43M invested in Lunai Bioworks in 2019 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

21% more capital invested

Capital invested by funds: $5.31M → $6.43M (+$1.11M)

0% more funds holding

Funds holding: 2929 (0)

0% less ownership

Funds ownership: 0.04%0.04% (-0%)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

11% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 9

Holders
29
Holders Change
Holders Change %
0%
% of All Funds
0.63%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
8
Reduced
9
Closed
4
Calls
Puts
Net Calls
Net Calls Change

LNAI Hedge Fund Activity: Q3 2019 in Review

29 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Lunai Bioworks (LNAI) for Q3 2019, worth a combined $6.43M — up 21% from $5.31M a quarter earlier.

Fund positioning in LNAI was balanced in Q3 2019: 4 funds opened new positions, 4 closed out, 8 added to existing stakes and 9 trimmed.

The largest buyer was United Capital Financial Advisors, adding an estimated $241K. The largest seller was Millennium Management, cutting an estimated $246K.

  • 29 institutional investors held Lunai Bioworks (LNAI) as of Q3 2019, unchanged from Q2 2019.
  • Funds reported $6.43M of Lunai Bioworks stock for Q3 2019, up 21% quarter-over-quarter.
  • 4 funds opened new Lunai Bioworks positions in Q3 2019 and 4 closed out, a net change of 0 holders.
  • The largest Lunai Bioworks buyer in Q3 2019 was United Capital Financial Advisors, an estimated $241K added.
  • The largest Lunai Bioworks seller in Q3 2019 was Millennium Management, an estimated $246K sold.

Based on aggregated 13F filings for Q3 2019.